

TABLE 2. Clinical Characteristics of U.S. Active Component Service Members with Guillain-Barré Syndrome, 2014–2022

Clinical Feature	No.	% ^a
Total	191	100
Antecedent clinical event		
Preceding illness only	94	49.2
Preceding immunization only	28	14.7
Both preceding illness and immunization	46	24.1
No preceding illness or immunization	23	12.0
Pain present, acute phase		
Yes	141	73.8
No	50	26.2
Modified Rankin Scale nadir		
MRS 0 (no symptoms)	0	0.0
MRS 1 (no significant disability)	40	20.9
MRS 2 (slight disability)	71	37.2
MRS 3 (moderate disability)	33	17.3
MRS 4 (moderately severe disability)	29	15.2
MRS 5 (severe disability)	16	8.4
Unknown	2	1.0
Hospitalization		
Yes	177	92.7
No	14	7.3
Median duration	7 days (2–54)	
Mechanical ventilation required		
Yes	20	10.4
No	171	89.6
Primary treatment		
IVIG	155	81.2
None	11	5.8
IVIG/PLEX	11	5.8
PLEX	7	3.7
Steroids	7	3.7
Neuropathic pain treatment		
Yes	92	48.2
No	99	51.8
Electrodiagnostic testing completed		
Yes	108	56.5
No	83	43.5
Results of electrodiagnostic testing		
Not completed	83	43.5
Demyelinating	53	27.7
Axonal, mixed	28	14.7
Normal	27	14.1

Abbreviations: No., number; MRS, Modified Rankin Scale; IVIG, intravenous immunoglobulins; PLEX, plasma exchange.

^aRow percentage calculated from total cases defined with clinical feature.